The acute phase response in panic disorder

International Journal of Neuropsychopharmacology

Volumn 8, Issue 4, 2005, Pages 529-535

  Herrán, Andrés ^a,b   Sierra Biddle, Deirdre ^a   García Unzueta, Maria Teresa ^a   Puente, Jesús ^a   Vázquez Barquero, José Luis ^a   Amado, José Antonio ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Acute phase proteins; Acute phase response; Anxiety disorders; Hypothalamo hypophyseal system; Panic disorder; Serotonin uptake inhibitors

Indexed keywords

ACUTE PHASE PROTEIN; ALBUMIN; C REACTIVE PROTEIN; FIBRINOGEN; HYDROCORTISONE; IMMUNOGLOBULIN; SEROTONIN UPTAKE INHIBITOR;

ACUTE PHASE RESPONSE; ADULT; AGE DISTRIBUTION; AGORAPHOBIA; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HYDROCORTISONE BLOOD LEVEL; INTERVIEW; LABORATORY TEST; MALE; MEDICAL ASSESSMENT; MINI MENTAL STATE EXAMINATION; PANIC; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGIC TEST; RATING SCALE; SEX RATIO;

ACUTE DISEASE; ACUTE-PHASE PROTEINS; ADULT; AGORAPHOBIA; FEMALE; HUMANS; HYDROCORTISONE; INTERVIEW, PSYCHOLOGICAL; MALE; PANIC DISORDER; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 25844451313     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145705005432     Document Type: Article

References (26)

1. Abelson JL, Curtis GC, Cameron OG (1996). Hypothalamic-pituitary-adrenal axis activity in panic disorder: effects of alprazolam on 24 h secretion of adrenocorticotropin and cortisol. Journal of Psychiatric Research 30, 79-93.
2. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (4th edn). Washington, DC: American Psychiatric Association.
3. Argyropoulos SV, Bailey JE, Hood SD, Kendrick AH, Rich AS, Laszlo G, Nash JR, Lightman SL, Nutt DJ (2002). Inhalation of 35% CO(2) results in activation of the HPA axis in healthy volunteers. Psychoneuroendocrinology 27, 715-729.
4. Barkhudaryan N, Dunn AJ (1999). Molecular mechanisms of actions of interleukin-6 on the brain, with special reference to serotonin and the hypothalamo-pituitary-adrenocortical axis. Neurochemistry Research 24, 1169-1180.
5. Berk M, Wadee AA, Kuschke RH, O'Neill-Kerr A (1997). Acute phase proteins in major depression. Journal of Psychosomatic Research 43, 529-534.
6. Boyer P (2000). Do anxiety and depression have a common pathophysiological mechanism? Acta Psychiatrica Scandinavica 102 (Suppl. 406), 24-29.
7. Craske MG, Barlow DH (1989). Nocturnal panic. Journal of Nervous and Mental Disease 177, 160-168.
8. Gabay C, Kushner I (1999). Acute-phase proteins and other systemic responses to inflammation. New England Journal of Medicine 340, 448-454.
9. Guy W (Ed.). (1976). ECDEU Assessment Manual for Psychopharmacology, Revised (pp. 76-338). Rockville, MD: National Institute of Mental Health. Department of Health, Education, and Welfare publication (ADM).
10. Kessler RC (2001). Comorbidity of depression and anxiety disorders. In: Montgomery SA, den Boer JA (Eds.), SSRIs in Depression and Anxiety (2nd edn) (pp. 87-106). John Wiley & Sons Ltd.
11. Leonard BE (2001). The immune system, depression and the action of antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry 25, 767-780.
12. Lin A, Kenis G, Bignotti S, Tura GJB, De Jong R, Bosmans E, Pioli R, Altamura C, Scharpe S, Maes M (1998). The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophrenia Research 32, 9-15.
13. Maes M, Meltzer HY, Bosmans E (1994). Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatrica Scandinavica 89, 346-351.
14. Maes M, Scharpe S, Meltzer HY, Bosmans E, Suy E, Calabrese J, Cosyns P (1993). Relationships between interleukin-6 activity, acute phase proteins and HPA-axis function in severe depression. Psychiatry Research 49, 11-27.
15. Maes M, Scharpe S, Neels H, Wauters A, Van Gastel A, Cosyns P (1995). Total serum protein and serum protein fractions in major depression. Journal of Affective Disorders 34, 61-69.
16. Millon T (1987). Millon Clinical Multiaxial Inventory Manual II. Minneapolis: National Computer Systems.
17. Schreiber W, Lauer CJ, Krumrey K, Holsboer F, Krieg JC (1996). Dysregulation of the hypothalamic-pituitary-adrenocortical system in panic disorder. Neuropsychopharmacology 15, 7-15.
18. Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW, Gorman JM, Papp LA (1997). Multicenter collaborative panic disorder severity scale. American Journal of Psychiatry 154, 1571-1575.
19. Shear MK, Clark D, Feske U (1998). The road to recovery in panic disorder: response, remission, and relapse. Journal of Clinical Psychiatry 59 (Suppl. 8), 4-8.
20. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janaus J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998). The Mini-International Neuropsychiatric Interview (MINI). Journal of Clinical Psychiatry 59 (Suppl. 20), 22-33.
21. Sluzewska A, Rybakowski J, Bosmans E, Sobieska M, Berghmans R, Maes M, Wiktorowicz K (1996). Indicators of immune activation in major depression. Psychiatry Research 64, 161-167.
22. Spielberger CD, Gorsuch RL, Lushene RE (1970). Manual to the State-Trait Inventory. Palo Alto: Consulting Psychologists Press.
23. van West D, Maes M (1999). Activation of the inflammatory response system: a new look at the etiopathogenesis of major depression. Neuroendocrinology Letters 20, 11-17.
24. Wedekind D, Bandelow B, Broocks A, Hajak G, Rüther E (2000). Salivary, total plasma and plasma free cortisol in panic disorder. Journal of Neural Transmission 107, 831-837.
25. Weissman M, Bland R, Canino G, Faravelli C, Greenwald S, Hwu HG, et al. (1997). The cross-national epidemiology of panic disorder. Archives of General Psychiatry 54, 305-309.
26. Whicher JT (1990). Acute phase proteins, physiology and clinical uses. Clinical Biochemistry Reviews 11, 4-9.